3-甲氧基-2-萘醛 | 56679-88-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-甲氧基-2-萘醛
• 英文名称: 3-methoxy-naphthalene-2-carbaldehyde
• 英文别名: 3-methoxy-2-naphthaldehyde；3-methoxynaphthalene-2-carbaldehyde
• CAS: 56679-88-0
• 化学式: C₁₂H₁₀O₂
• mdl: MFCD13191799
• 分子量: 186.21
• InChiKey: OQDOWNJLYIFTHK-UHFFFAOYSA-N

物化性质

• 熔点：
  92 °C
• 沸点：
  347.1±15.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2912499000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，使用惰性气体保护。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methoxy-2-naphthaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methoxy-2-naphthaldehyde
CAS number: 56679-88-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H10O2
Molecular weight: 186.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲氧基-2-萘醛 在 磷化氢 、 氢溴酸 、 一水合肼 、 乙二醇 、 溶剂黄146 作用下， 反应 2.0h， 生成 2-羟基-3-甲基萘
  参考文献：
  名称：

  Huisgen; Nakaten, Justus Liebigs Annalen der Chemie, 1954, vol. 586, p. 84,107

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-3-萘甲酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 乙醚 、 丙酮 为溶剂， 反应 63.0h， 生成 3-甲氧基-2-萘醛
  参考文献：
  名称：

  抗结核分枝杆菌的新型三芳基二甲基氨基丁烷-2-醇衍生物的设计，合成和生物学评价。

  摘要：

  Bedaquiline（TMC207）是一种典型的二芳基喹啉抗结核药，已被FDA批准用于治疗MDR-TB。在这里，我们描述了从TMC207的结构修饰获得的一系列三芳基二甲基氨基丁烷-2-醇衍生物的抗结核分枝杆菌的设计，合成和体外生物学评价。化合物23，25，28，32，39和43提供优于比阳性对照抗分枝杆菌活性的PC01，其示出了相同的结构，并包含TMC207。化合物16，20，29，34，37，45和47表现出相似的活性的阳性对照PC01。最重要的是，该系列化合物显示出优异的抗XDR-Mtb活性。急性毒性的结果表明，这类三芳基二甲基氨基丁烷-2-醇衍生物应分级为低。进一步的SAR分析表明，较大的空间体积的三芳基和1-萘基上的7-Br，3-OCH 3是至关重要的。

  DOI：

  10.1016/j.bioorg.2020.104054

文献信息

• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Molecular Tweezers: Synthesis and Formation of Host-Guest Complexes
  作者：Béatrice Legouin、Maud Gayral、Philippe Uriac、Jean-François Cupif、Nicolas Levoin、Loic Toupet、Pierre van de Weghe

  DOI：10.1002/ejoc.201000729

  日期：——

  A chiral molecular tweezer obtained from (+)-usnic acid placed in solution in the presence of various aromatic compounds afforded complexes with low association constants. Thus, the X-ray structure of assembly 3i is presented, where the guest is sandwiched between the two pincers of the tweezer. The association constants for various guests were determined through different methods. Finally, other tweezers

  在各种芳香族化合物存在的情况下，从 (+)-usnic 酸溶液中获得的手性分子镊子提供了具有低缔合常数的复合物。因此，呈现组件 3i 的 X 射线结构，其中客体夹在镊子的两个钳子之间。各种客人的关联常数是通过不同的方法确定的。最后，由 (1R,2R)-1,2-二氨基环己烷制备了其他带有富电子芳香醛和酮的镊子。最有趣的配合物也通过结构分析得到证实，并且以 10-羟基菲-9-甲醛 (5i) 作为芳香部分获得了最好的结果。
• [EN] PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DES PGE2
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210988A1

  公开（公告）日：2018-11-22

  The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式(I)的嘧啶衍生物，其中(R1)n，R3，R4a，R4b，R5a，R5b和Ar1如描述中所述，以及它们通过调节免疫反应，包括肿瘤中免疫系统的再激活，用于治疗癌症。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(II)，及其作为药物的使用，其制备，药用可接受的盐，及其作为药物的使用，以及包含式(I)中一个或多个化合物的药物组合物，尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
• Indole derivative having piperidine ring
  申请人：Suzuki Yuichi

  公开号：US20050256103A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

  本发明涉及以下公式所代表的化合物，其药学上可接受的盐，或其作为药物的用途： 其中R1和R2是相邻的取代基，与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物，该基可能被1至4个取代基所取代，所述取代基选自（1）氧代基，（2）羟基等；R3代表氢原子或类似物；R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状，特别是涉及尿液储存的症状的药剂，该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
• Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters
  申请人：Zhao Yigang

  公开号：US20120302752A1

  公开（公告）日：2012-11-29

  Methods are described for efficient and regioselective reactions that are Ru-catalyzed and either (i) amide-directed C—H, C—N, C—O activation/C—C bond forming reactions, (ii) ester-directed C—O and C—N activation/C—C bond forming reactions, or (iii) amide-directed C—O activation/hydrodemethoxylation reactions. All of these reactions of directed C—H, C—N, C—O activation/coupling reactions establish a catalytic base-free DoM-cross coupling process at non-cryogenic temperature. High regioselectivity, yields, operational simplicity, low cost, and convenient scale-up make these reactions suitable for industrial applications. Many previously unknown amide-substituted or ester-substituted aryl and heteroaryl compounds are presented with synthetic details also provided.

  描述了一种高效和区域选择性反应的方法，这些反应是以钌为催化剂的，可以是（i）酰胺导向的C—H、C—N、C—O活化/C—C键形成反应，（ii）酯导向的C—O和C—N活化/C—C键形成反应，或者（iii）酰胺导向的C—O活化/脱甲氧基反应。所有这些导向C—H、C—N、C—O活化/偶联反应在非低温下建立了一个无催化剂碱的DoM-交叉偶联过程。高区域选择性、产率、操作简便、低成本和便于放大规模使得这些反应适用于工业应用。还提供了许多以前未知的酰胺取代或酯取代的芳基和杂环芳基化合物，同时提供了合成细节。